Will Teva's Deal With FTC Change Future Patent Litigation Settlements?

Settlement reflects existing landscape in which companies are avoiding no-authorized generic commitments, and may harbinger FTC's shift to other issues.

Silhouette woman to jump over obstacles over precipice between rocky mountains A Step to success at background sunset pastel.

After nearly a decade of litigation, Teva Pharmaceutical Industries Ltd. has acquiesced to the Federal Trade Commission's demands, agreeing to exclude no-authorized generic commitments from future patent litigation settlements. While it is a win for the Commission, attorneys don't expect it to have much of an impact since companies have already been crafting deals to avoid FTC's ire.

Teva's global settlement resolves three FTC lawsuits and modifies the terms of a 2015 consent decree with Teva subsidiary